<p><strong>本公告所包含的信息被公司视为根据市场滥用条例（EU）第 596/2014 条款所规定的内部信息，因其作为 2018 年欧洲联盟（撤回）法案的一部分构成英国国内法。通过监管信息服务发布本公告后，该信息被视为公开信息。</strong></p>
<p><strong>Genflow Biosciences Plc</strong></p>
<p><strong>获得瓦隆大区对 GF-100 的 400 万欧元资金支持的行政批准；以及 2026 年发展优先事项</strong></p>
<p>Genflow Biosciences Plc（伦敦证券交易所代码：GENF）（OTCQB 代码：GENFF）（&#34;Genflow&#34;或&#34;公司&#34;），是一家专注于开发与年龄相关疾病基因疗法的欧洲生物技术公司，宣布获得比利时瓦隆大区约 400 万欧元的非稀释性财政支持的行政批准，此前瓦隆大区部长 Adrien Dolimont 已签署同意。</p>
<p>一旦收到资金，将支持公司主要基因疗法候选药物 GF-1002 的持续开发，以治疗代谢功能障碍相关性脂肪肝炎（&#34;MASH&#34;）。关于该奖励的原始公告可以在此找到。</p>
<p>第一笔款项的发放预计不晚于 2026 年 5 月。该支持方案涵盖为期三年的开发计划，并与 Genflow 现有的路线图相一致。2025 年期间发生的所有项目相关费用将符合该计划的条款。</p>
<p><strong>2026 年发展优先事项</strong></p>
<p>在 2026 年，Genflow 的战略强调管道纪律和资本效率，优先考虑数据最强、价值创造路径最清晰、合作潜力最高的项目。该方法的核心是追求早期合作协议，以确保非稀释性资金，提供平台的外部验证，并支持持续开发。</p>
<p>随着多个预期数据的发布、不断扩展的合作伙伴对话以及日益成熟的知识产权状况，Genflow 相信自己在进入下一个发展阶段时处于良好位置，同时保持对科学严谨性、运营执行和长期股东价值创造的关注。</p>
<p><strong>犬类衰老研究（GF-1004）</strong></p>
<p>正在进行的 GF-1004 犬类衰老研究于 2025 年 3 月开始，作为一项盲法临床试验，旨在评估与肌肉减少症、健康寿命和寿命相关的生物标志物的潜在益处。</p>
<p>预计将在 2026 年第一季度获得初步疗效结果。参与研究的犬只将在 180 天内进行监测，计划在六个月时进行第二次疗效评估。该后续评估的结果预计将在 2026 年 6 月至 7 月公布，旨在评估疗效的持久性和长期效果。</p>
<p><strong>青光眼项目</strong></p>
<p>公司的青光眼项目将优先考虑交付优化和执行准备。Genflow 正在与一家领先的脂质纳米颗粒（LNP）合作伙伴进行讨论，以支持交付创新，并正在推进选择一家全方位服务的合同研究组织（CRO），以管理基于 RNA 的配方活动，直至临床前执行。</p>
<p><strong>其他项目</strong></p>
<p>在更广泛的管道中，Genflow 继续按照既定开发计划推进其肌肉减少症项目。同时，ExoFastTrack 计划继续生成数据，旨在支持和加速多个项目的进展。</p>
<p>Genflow 首席执行官 Eric Leire 博士评论道：&#34;这项资金的行政批准强化了我们在 2026 年发展优先事项上以纪律和专注执行的能力。它增强了我们推进 GF-1002 的能力，同时在更广泛的管道中保持选择性和数据驱动的方法。随着我们进入新的一年，我们的重点仍然是具有明确执行路径、强大科学依据和有意义的合作及非稀释性价值创造机会的项目。&#34;</p>
<p><strong>联系方式</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genflow Biosciences</strong></td>
<td><strong>Harbor Access</strong></td>
</tr>
<tr>
<td>Dr Eric Leire, CEO</td>
<td>Jonathan Paterson, 投资关系</td>
</tr>
<tr>
<td>+32-477-495-881</td>
<td>+1 475 477 9401</td>
</tr>
<tr>
<td></td>
<td>Jonathan.Paterson@Harbor-access.com</td>
</tr>
</tbody>
</table>
<p><strong>关于 Genflow Biosciences</strong></p>
<p>Genflow Biosciences Plc（伦敦证券交易所代码：GENF）（OTCQB 代码：GENFF）成立于 2020 年，总部位于英国，在比利时设有研发设施，致力于开发与年龄相关疾病的基因疗法，旨在促进更长寿和更健康的生活，同时减轻快速增长的老龄化全球人口所带来的经济、情感和社会影响。Genflow 的主要化合物 GF-1002 通过传递一种百岁老人的 SIRT6 基因变体来发挥作用，已取得令人鼓舞的临床前结果。Genflow 的 12 个月概念验证临床试验评估其 SIRT6-百岁老人基因疗法在老年犬中的效果于 2025 年 3 月开始。其他项目包括一项临床试验，将探讨 GF-1002 在治疗 MASH（代谢功能障碍相关性脂肪肝炎）中的潜在益处，这是一种没有有效治疗方法的最常见慢性肝病。请访问 www.genflowbio.com 并在 LinkedIn 和 X 上关注公司。</p>
<p><strong>免责声明</strong></p>
<p>本公告的内容由公司准备，并由公司独自负责。</p>
<p>本公告可能包含前瞻性声明。前瞻性声明包括但不限于关于公司或董事对未来的期望、希望、信念、意图或战略的声明。此外，任何提及预测、预期或其他对未来事件或情况的描述，包括任何基本假设的声明，均为前瞻性声明。&#34;预期&#34;、&#34;相信&#34;、&#34;继续&#34;、&#34;可能&#34;、&#34;估计&#34;、&#34;期望&#34;、&#34;打算&#34;、&#34;或许&#34;、&#34;可能&#34;、&#34;计划&#34;、&#34;潜在&#34;、&#34;预测&#34;、&#34;项目&#34;、&#34;寻求&#34;、&#34;应该&#34;、&#34;会&#34;及类似表达，或在每种情况下其否定形式，可能识别为前瞻性声明，但缺乏这些词并不意味着该声明不是前瞻性的。</p>
<p>前瞻性声明包括所有非历史事实的事项。前瞻性声明基于对公司、业务、经济及其他未来条件的当前期望和假设。由于前瞻性声明涉及未来，因此本质上，它们受到固有的不确定性、风险和难以预测的情况变化的影响。前瞻性声明并不保证未来的表现，公司实际的财务状况、实际的运营结果和财务表现，以及其经营或将经营的行业的发展，可能与本公告中包含或暗示的前瞻性声明大相径庭。此外，即使公司的财务状况、运营结果及其经营或将经营的行业的发展与本公告中包含的前瞻性声明一致，这些结果或发展也可能不代表后续期间的财务状况、运营结果或发展。可能导致实际结果与前瞻性声明中所述结果大相径庭的重要因素包括区域、国家或全球的政治、经济、社会、商业、技术、竞争、市场和监管条件。</p>
<p>本公告中包含的任何前瞻性声明仅适用于本公告的日期，并且完全受到这些警示声明的明确限定。可能导致公司实际计划或结果有所不同的因素或事件可能会不时出现，公司无法预测所有这些因素。除非法律、招股说明书规则、上市规则、FCA 的披露指导和透明度规则或英国市场滥用法规要求，否则公司明确声明不承担任何义务或承诺，公开发布任何前瞻性声明的更新或修订，以反映其期望的任何变化或本公告中任何前瞻性声明所基于的事件、条件或情况的任何变化。</p>
<p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p><strong>来源：</strong> Genflow Biosciences PLC</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMTEzNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMTEzNg"/></p>

医疗业 ETF - Vanguard

生物科技ETF基金

动态制药业投资组合 ETF - Invesco

<p>Genflow Biosciences PLC 已获得瓦隆大区行政批准，获得 400 万欧元的资金支持，用于开发其基因治疗候选药物 GF-1002，以治疗代谢功能障碍相关性脂肪肝炎（MASH）。预计这笔资金将在 2026 年 5 月之前发放，并与公司 2026 年的发展优先事项相一致，重点关注资本效率和早期阶段的合作。首席执行官 Dr. Eric Leire 强调了这笔资金在推进他们的产品线和保持数据驱动方法中的重要性</p>

<p><strong>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.</strong></p>
<div class="lb-trans"><p><strong>本公告所包含的信息被公司视为根据市场滥用条例（EU）第 596/2014 条款所规定的内部信息，因其作为 2018 年欧洲联盟（撤回）法案的一部分构成英国国内法。通过监管信息服务发布本公告后，该信息被视为公开信息。</strong></p>
</div><p><strong>Genflow Biosciences Plc</strong></p>
<div class="lb-trans"><p><strong>Genflow Biosciences Plc</strong></p>
</div><p><strong>Administrative Approval of €4 Million Funding Support from Wallonia Region for GF-100; and 2026 Development Priorities</strong></p>
<div class="lb-trans"><p><strong>获得瓦隆大区对 GF-100 的 400 万欧元资金支持的行政批准；以及 2026 年发展优先事项</strong></p>
</div><p>Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&#34;Genflow&#34; or the &#34;Company&#34;), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces the administrative approval of the previously announced award of approximately €4 million in non-dilutive financial support from the Wallonia Region of Belgium, following the assenting signature of Minister Adrien Dolimont.</p>
<div class="lb-trans"><p>Genflow Biosciences Plc（伦敦证券交易所代码：GENF）（OTCQB 代码：GENFF）（&#34;Genflow&#34;或&#34;公司&#34;），是一家专注于开发与年龄相关疾病基因疗法的欧洲生物技术公司，宣布获得比利时瓦隆大区约 400 万欧元的非稀释性财政支持的行政批准，此前瓦隆大区部长 Adrien Dolimont 已签署同意。</p>
</div><p>The funding, once received, will support the continued development of the Company's lead gene therapy candidate, GF-1002, for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (&#34;MASH&#34;). The original RNS announcing the award can be found here.</p>
<div class="lb-trans"><p>一旦收到资金，将支持公司主要基因疗法候选药物 GF-1002 的持续开发，以治疗代谢功能障碍相关性脂肪肝炎（&#34;MASH&#34;）。关于该奖励的原始公告可以在此找到。</p>
</div><p>Disbursement of the first instalment is expected no later than May 2026. The support package spans a three-year development programme and is aligned with Genflow's existing roadmap. All project-related expenses incurred during 2025 will be eligible under the terms of the programme.</p>
<div class="lb-trans"><p>第一笔款项的发放预计不晚于 2026 年 5 月。该支持方案涵盖为期三年的开发计划，并与 Genflow 现有的路线图相一致。2025 年期间发生的所有项目相关费用将符合该计划的条款。</p>
</div><p><strong>Development Priorities for 2026</strong></p>
<div class="lb-trans"><p><strong>2026 年发展优先事项</strong></p>
</div><p>In 2026 Genflow's strategy emphasises pipeline discipline and capital efficiency, prioritising programmes with the strongest data, the clearest paths to value creation, and the highest potential for partner engagement. Central to this approach is the pursuit of early-stage collaboration agreements designed to secure non-dilutive funding, provide external validation of the platform, and support continued development.</p>
<div class="lb-trans"><p>在 2026 年，Genflow 的战略强调管道纪律和资本效率，优先考虑数据最强、价值创造路径最清晰、合作潜力最高的项目。该方法的核心是追求早期合作协议，以确保非稀释性资金，提供平台的外部验证，并支持持续开发。</p>
</div><p>With multiple anticipated data readouts, an expanding partner dialogue, and a maturing intellectual property position, Genflow believes it is well positioned to enter its next phase of development while maintaining a focus on scientific rigour, operational execution, and long-term shareholder value creation.</p>
<div class="lb-trans"><p>随着多个预期数据的发布、不断扩展的合作伙伴对话以及日益成熟的知识产权状况，Genflow 相信自己在进入下一个发展阶段时处于良好位置，同时保持对科学严谨性、运营执行和长期股东价值创造的关注。</p>
</div><p><strong>Dog Aging (GF-1004)</strong></p>
<div class="lb-trans"><p><strong>犬类衰老研究（GF-1004）</strong></p>
</div><p>The ongoing GF-1004 dog aging study, which commenced in March 2025, is being conducted as a blinded clinical trial designed to assess potential benefits related to sarcopenia, healthspan, and lifespan-associated biomarkers.</p>
<div class="lb-trans"><p>正在进行的 GF-1004 犬类衰老研究于 2025 年 3 月开始，作为一项盲法临床试验，旨在评估与肌肉减少症、健康寿命和寿命相关的生物标志物的潜在益处。</p>
</div><p>An initial efficacy readout is expected in the first quarter of 2026. Dogs enrolled in the study are being monitored over a 180-day period, with a second efficacy assessment planned at the six-month timepoint. Results from this later evaluation are expected in June-July 2026 and are intended to assess durability and longer-term effects.</p>
<div class="lb-trans"><p>预计将在 2026 年第一季度获得初步疗效结果。参与研究的犬只将在 180 天内进行监测，计划在六个月时进行第二次疗效评估。该后续评估的结果预计将在 2026 年 6 月至 7 月公布，旨在评估疗效的持久性和长期效果。</p>
</div><p><strong>Glaucoma Programme</strong></p>
<div class="lb-trans"><p><strong>青光眼项目</strong></p>
</div><p>The Company's glaucoma programme will prioritise delivery optimisation and execution readiness. Genflow is advancing discussions with a leading lipid nanoparticle (LNP) partner to support delivery innovation and is progressing the selection of a full-service contract research organisation (CRO) to manage RNA-based formulation activities through preclinical execution.</p>
<div class="lb-trans"><p>公司的青光眼项目将优先考虑交付优化和执行准备。Genflow 正在与一家领先的脂质纳米颗粒（LNP）合作伙伴进行讨论，以支持交付创新，并正在推进选择一家全方位服务的合同研究组织（CRO），以管理基于 RNA 的配方活动，直至临床前执行。</p>
</div><p><strong>Additional Programmes</strong></p>
<div class="lb-trans"><p><strong>其他项目</strong></p>
</div><p>Across the broader pipeline, Genflow continues to advance its sarcopenia programme in line with established development plans. In parallel, the ExoFastTrack initiative continues to generate data intended to support and accelerate multiple programmes across the portfolio.</p>
<div class="lb-trans"><p>在更广泛的管道中，Genflow 继续按照既定开发计划推进其肌肉减少症项目。同时，ExoFastTrack 计划继续生成数据，旨在支持和加速多个项目的进展。</p>
</div><p>Dr. Eric Leire, CEO of Genflow, commented: &#34;The administrative approval of this funding reinforces our ability to execute against our 2026 development priorities with discipline and focus. It strengthens our capacity to advance GF-1002 while maintaining a selective, data-driven approach across the broader pipeline. As we enter the coming year, our emphasis remains on programmes with clear execution paths, strong scientific rationale, and meaningful opportunities for partnership and non-dilutive value creation.&#34;</p>
<div class="lb-trans"><p>Genflow 首席执行官 Eric Leire 博士评论道：&#34;这项资金的行政批准强化了我们在 2026 年发展优先事项上以纪律和专注执行的能力。它增强了我们推进 GF-1002 的能力，同时在更广泛的管道中保持选择性和数据驱动的方法。随着我们进入新的一年，我们的重点仍然是具有明确执行路径、强大科学依据和有意义的合作及非稀释性价值创造机会的项目。&#34;</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genflow Biosciences</strong></td>
<td><strong>Harbor Access</strong></td>
</tr>
<tr>
<td>Dr Eric Leire, CEO</td>
<td>Jonathan Paterson, Investor Relations</td>
</tr>
<tr>
<td>+32-477-495-881</td>
<td>+1 475 477 9401</td>
</tr>
<tr>
<td></td>
<td>Jonathan.Paterson@Harbor-access.com</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genflow Biosciences</strong></td>
<td><strong>Harbor Access</strong></td>
</tr>
<tr>
<td>Dr Eric Leire, CEO</td>
<td>Jonathan Paterson, 投资关系</td>
</tr>
<tr>
<td>+32-477-495-881</td>
<td>+1 475 477 9401</td>
</tr>
<tr>
<td></td>
<td>Jonathan.Paterson@Harbor-access.com</td>
</tr>
</tbody>
</table>
</div><p><strong>About Genflow Biosciences</strong></p>
<div class="lb-trans"><p><strong>关于 Genflow Biosciences</strong></p>
</div><p>Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&amp;D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.</p>
<div class="lb-trans"><p>Genflow Biosciences Plc（伦敦证券交易所代码：GENF）（OTCQB 代码：GENFF）成立于 2020 年，总部位于英国，在比利时设有研发设施，致力于开发与年龄相关疾病的基因疗法，旨在促进更长寿和更健康的生活，同时减轻快速增长的老龄化全球人口所带来的经济、情感和社会影响。Genflow 的主要化合物 GF-1002 通过传递一种百岁老人的 SIRT6 基因变体来发挥作用，已取得令人鼓舞的临床前结果。Genflow 的 12 个月概念验证临床试验评估其 SIRT6-百岁老人基因疗法在老年犬中的效果于 2025 年 3 月开始。其他项目包括一项临床试验，将探讨 GF-1002 在治疗 MASH（代谢功能障碍相关性脂肪肝炎）中的潜在益处，这是一种没有有效治疗方法的最常见慢性肝病。请访问 www.genflowbio.com 并在 LinkedIn 和 X 上关注公司。</p>
</div><p><strong>DISCLAIMER</strong></p>
<div class="lb-trans"><p><strong>免责声明</strong></p>
</div><p>The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.</p>
<div class="lb-trans"><p>本公告的内容由公司准备，并由公司独自负责。</p>
</div><p>This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words &#34;anticipate&#34;, &#34;believe&#34;, &#34;continue&#34;, &#34;could&#34;, &#34;estimate&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;may&#34;, &#34;might&#34;, &#34;plan&#34;, &#34;possible&#34;, &#34;potential&#34;, &#34;predict&#34;, &#34;project&#34;, &#34;seek&#34;, &#34;should&#34;, &#34;would&#34; and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.</p>
<div class="lb-trans"><p>本公告可能包含前瞻性声明。前瞻性声明包括但不限于关于公司或董事对未来的期望、希望、信念、意图或战略的声明。此外，任何提及预测、预期或其他对未来事件或情况的描述，包括任何基本假设的声明，均为前瞻性声明。&#34;预期&#34;、&#34;相信&#34;、&#34;继续&#34;、&#34;可能&#34;、&#34;估计&#34;、&#34;期望&#34;、&#34;打算&#34;、&#34;或许&#34;、&#34;可能&#34;、&#34;计划&#34;、&#34;潜在&#34;、&#34;预测&#34;、&#34;项目&#34;、&#34;寻求&#34;、&#34;应该&#34;、&#34;会&#34;及类似表达，或在每种情况下其否定形式，可能识别为前瞻性声明，但缺乏这些词并不意味着该声明不是前瞻性的。</p>
</div><p>Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.</p>
<div class="lb-trans"><p>前瞻性声明包括所有非历史事实的事项。前瞻性声明基于对公司、业务、经济及其他未来条件的当前期望和假设。由于前瞻性声明涉及未来，因此本质上，它们受到固有的不确定性、风险和难以预测的情况变化的影响。前瞻性声明并不保证未来的表现，公司实际的财务状况、实际的运营结果和财务表现，以及其经营或将经营的行业的发展，可能与本公告中包含或暗示的前瞻性声明大相径庭。此外，即使公司的财务状况、运营结果及其经营或将经营的行业的发展与本公告中包含的前瞻性声明一致，这些结果或发展也可能不代表后续期间的财务状况、运营结果或发展。可能导致实际结果与前瞻性声明中所述结果大相径庭的重要因素包括区域、国家或全球的政治、经济、社会、商业、技术、竞争、市场和监管条件。</p>
</div><p>Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.</p>
<div class="lb-trans"><p>本公告中包含的任何前瞻性声明仅适用于本公告的日期，并且完全受到这些警示声明的明确限定。可能导致公司实际计划或结果有所不同的因素或事件可能会不时出现，公司无法预测所有这些因素。除非法律、招股说明书规则、上市规则、FCA 的披露指导和透明度规则或英国市场滥用法规要求，否则公司明确声明不承担任何义务或承诺，公开发布任何前瞻性声明的更新或修订，以反映其期望的任何变化或本公告中任何前瞻性声明所基于的事件、条件或情况的任何变化。</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p><strong>SOURCE:</strong> Genflow Biosciences PLC</p>
<div class="lb-trans"><p><strong>来源：</strong> Genflow Biosciences PLC</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMTEzNg" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1131136"/></p>

Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities | GENFF Stock News

StockTitan

标普制药指数 ETF - SPDR

标普全球医疗股指数 ETF - iShares

国泰中证生物医药ETF

广发中证全指医药卫生ETF

基因改革 ETF - ARK

华夏上证科创板生物医药ETF

制药 ETF - VanEck Vectors

医疗业 ETF - SPDR

易方达沪深300医药ETF

美国制药 ETF - iShares

Genflow Biosciences PLC 宣布获得行政批准的授予及 2026 年优先事项 | GENFF 股票新闻